serum albumin. Thus if an excess of bilirubin is added to human serum albumin or to neonatal serum in buffer containing 0.1 mol of tris(hydroxymethyl)aminomethane and 2.0 mol of NaCI per liter (pH 7.5), and the bilirubin not bound to albumin is removed by treatment with calcium carbonate, the bilirubin binding reserve of primary binding sites can be estimated from direct measurement of spectral absorbance at 468 nm. Hemolysis and conjugated bilirubin apparently do not interfere. in a comparison study with serum samples from neonates the method gave resuits that generally agreed with those obtained by a commercially available Sephadex G-25 column procedure. In serum samples from adults the calculated unbound unconjugated bilirubin (free bilirubin) values derived by using binding reserves determined by the proposed method correlated well with the free bilirubin concentrations measured by a peroxidase method, but were only about one-half the amounts obtained by the peroxidase method. 
Materials and Methods

Instrumentation
All spectrophotometric measurements were made with the Beckman ACTA CIII spectrophotometer (Scientific Instrument Div., Beckman Instruments, Inc., Irvine, CA 92664). The band width was 0.2 nm at 468 nm, with instrument programming at other wavelengths. Semimicro 1.0-cm cuvettes were used for all measurements.
A rotating mixer (Model 150, Scientific Industries, Inc., Springfield, MA 01103) with the rotation speed set at 5s per revolution was used in the basic procedure.
Reagents
Buffer grade Tris, 0.1 mol/L, was adjusted to pH 7.5; 0.1 mol/L Tris and 2.0 mol/L NaCI (Tris-salt buffer) was also adjusted to pH 7. Versatol has an excess of albumin, it was also used as a control in the method I describe for the estimation of primary-site bilirubin binding reserve.
Procedures
Calibration of biliru bin solutions. To 1.0 mL of appropriate Tris buffer add 20 zL of freshly reconstituted Pediatric Versatol. Five minutes after mixing, measure the absorbance of the solutions at 468 nm with buffer as reference. Calculate an absorptivity factor (F) as follows:
The calculation of F permits simple calculation of bilirubin values because any measured absorbances at 468 nm can be simply multiplied by F to obtain the bilirubin concentration. (13) to measure unbound unconjugated bilirubin (free bilirubin).
Other than performing it manually, I followed the procedure exactly.
Other methods. 
Results and Discussion
Calibration Spectrophotometric Scans Figure 1 shows scans of Tris buffer or Tris-salt containing 8.0 nmol of bilirubin before and after serial 2-jL additions of an albumin solution. It is apparent in Tris buffer that the spectral shift is almost complete after addition of 4.0 nmol of albumin, which strongly suggests that both primary and secondary binding sites are initially binding bilirubin. The isobestic point is poorly defined, suggesting a system consisting of mixed bilirubin-albumin complexes. There are profound spectral changes in the presence of 2.0 mol/L NaCl in the buffer. The spectral shift is consistent with the occurrence of but one kind of binding site for bilirubin for each molecule of albumin. The use of salt concentrations at 1.0 and 1.5 mol/L gave similar but less reproducible scans than that illustrated. A salt concentration of 2.5 mol/L drastically diminished bilirubin binding, probably because of protein denaturation.
Binding of Bilirubin by Albumin
I assayed solutions containing 7.8 nmol of human serum albumin and different concentrations of bilirubin by the proposed method in two series of analyses, one with Tris buffer and the other with Tris-salt buffer as diluent. If only primary-site binding was occurring, one would expect that a maximum of 7.8 nmol of bilirubin would be bound and excess bilirubin would be removed by the calcium carbonate treatment. As seen in Figure 2 , when Tris buffer was used as diluent, there was no plateau to indicate the occurrence of maximum binding at the primary site only; additional binding of bilirubin appeared to occur at secondary sites. With Tris-salt buffer as diluent, however, binding at secondary sites was suppressed, as demonstrated by a leveling off of bound bilirubin at approximately the primary-site saturation point of 7.8 nmol.
Effect of Albumin Concentration in the Proposed Assay
In preliminary studies with dilute human serum albumin solutions, some secondary site binding was apparent. For this reason, I added bilirubin equivalent to only 125 mg/L in assays involving less than 3.5 nmol of albumin; the 250 mg/L bilirubin solution was used for assays with more than 3.5 nmol of albumin. The data given in Figure 3 indicate the detection of nearly equimolar binding of bilirubin by albumin. The binding reserve obtained by the proposed method, the unconjugated bilirubin concentration (from total and conjugated assays), and the published affinity constant (14) of the primary site of albumin at room temperature, 2.0 X 108, were used to calculate the free bilirubin in the samples. Correlation of the calculated values with the peroxidase method values was good, as seen in Figure 4 . The calculated values, however, are about 50% of the measured values. In part, this low proportionality may be explained by the fact that the peroxidase method does not correct for any oxidation of bound bilirubin; alternatively, the affinity of the primary binding site of albumin for bilirubin may be enhanced by the high salt concentration used in the proposed method.
Comparison of Methods
Effect of Hemolysis and Conjugated Bilirubin
Ten visibly hemolyzed sara were used as samples, subjected only to the calcium carbonate treatment used in the proposed method with Tris-salt buffer as diluent. There was no difference in the absorbance at 468 nm before and after the treatment.
Ten serum samples with increased conjugated bilirubin concentrations (51 to 183 mg/L) were similarly subjected to the calcium carbonate treatment. The decrease in absorbance, due to adsorption or destruction of conjugated bilirubin, was less than 4.5 mg/L (.A <0.01) for all 10 sera. Thus the contributions of hemoglobin and conjugated bilirubin to absorbance at 468 nm were unaffected by the calcium carbonate treatment used in the proposed method.
The experimental evidence presented suggests that high salt concentrations suppress the secondary-salt binding of bilirubin by human serum albumin. With secondary sites apparently suppressed, bilirubin added to albumin or serum is bound only by primary sites. Surplus bilirubin remains unbound and is removable by a calcium carbonate treatment. The method I propose for the estimation of primary site binding reserve is not only simple to perform, it also is unaffected by high amounts of conjugated bilirubin. This advantage enables evaluation of bilirubin binding reserve in neonates with hepatic excretory insufficiency, which is not possible with Sephadex methods.
